Business
Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, is pleased to announce that it has entered into subscription agreements pursuant to which it proposes to complete a non-brokered private placement (the "Offering") with two non-arm's length parties (each an "Investor") of 3,450 unsecured convertible debentures of
About this update from Optimi Health Corp.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":1,"height":1,"url":"https://www.newsfilecorp.com/newsinfo/259200/202"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0JVBkFhVYbrdAGNZNJWO4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY7Y2Y9d2VicA--/https://www.newsfilecorp.com/newsinfo/259200/202","width":1,"height":1}},"lazy":false},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, is pleased to announce that it has entered into subscription agreements pursuant to which it proposes to complete a non-brokered private placement (the "Offering") with two non-arm's length parties (each an "Investor") of 3,450 unsecured convertible debentures of the Company (each a "Convertible Debenture") at a price of CAD$1,000 per Convertible Debenture for gross proceeds of CAD$3,450,000. The Convertible Debentures will bear interest at a rate of 15.0% per annum, calculated and payable quarterly in arrears in cash, maturing twelve (12) months or, if extended for an additional twelve (12) months by the Investor, from the date of issuance, twenty-four months (the "Maturity Date"). The principal amount of each Convertible Debenture will be convertible into common shares of the Company (each a "Common Share") at a conversion price of $0.15 (the "Conversion Price"), being the closing price of the Common Shares on the Canadian Securities Exchange (the "CSE") preceding the execution by each Investor of the subscription agreement for the Convertible Debentures. On the Maturity Date, any outstanding principal amount of the Convertible Debentures, plus any accrued and unpaid interest thereon, will be repaid by the Company in cash or, at the option of the Investors, through the issuance of Common Shares. No warrants are attached to the Convertible Debentures issued under the Offering.","length":1731,"tagName":"p"},{"type":"text","content":"The principal amount of the Convertible Debentures, in whole or in part, will be convertible into Common Shares at the Conversion Price at the option of the...